Candida periprosthetic joint infection: A rare and difficult-to-treat infection: A rare and difficult-to-treat infection

Laura Escolà-Vergé, Dolors Rodríguez-Pardo, Jaime Lora-Tamayo, Laura Morata, Oscar Murillo, Helem Vilchez, Luisa Sorli, Laura Guío Carrión, José Mª Barbero, Julián Palomino-Nicás, Alberto Bahamonde, Alfredo Jover-Sáenz, Natividad Benito, Rosa Escudero, Marta Fernandez Sampedro, Rafael Pérez Vidal, Lucía Gómez, Pablo S. Corona, Benito Almirante, Javier ArizaCarles Pigrau

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)


Background: Candida periprosthetic joint infection (CPJI) is a rare, difficult-to-treat disease. The purpose of this study was to evaluate the clinical characteristics and outcomes of CPJI treated with various surgical and antifungal strategies. Methods: We conducted a multicenter retrospective study of all CPJI diagnosed between 2003 and 2015 in 16 Spanish hospitals. Results: Forty-three patients included: median age, 75 years, and median Charlson Comorbidity Index score, 4. Thirty-four (79.1%) patients had ≥1 risk factor for Candida infection. Most common causative species were C. albicans and C. parapsilosis. Thirty-five patients were evaluable for outcome: overall, treatment succeeded in 17 (48.6%) and failed in 18 (51.4%). Success was 13/20 (67%) in patients with prosthesis removal and 4/15 (27%) with debridement and prosthesis retention (p = 0.041). All 3 patients who received an amphotericin B-impregnated cement spacer cured. In the prosthesis removal group, success was 5/6 (83%) with an antibiofilm regimen and 8/13 (62%) with azoles (p = 0.605). In the debridement and prosthesis retention group, success was 3/10 (30%) with azoles and 1/5 (20%) with antibiofilm agents. Therapeutic failure was due to relapse in 9 patients, need for suppressive treatment in 5, persistent infection in 2, and CPJI-related death in 2; overall attributable mortality was 6%. Conclusions: CPJI is usually a chronic disease in patients with comorbidities and risk factors for Candida infection. Treatment success is low, and prosthesis removal improves outcome. Although there is insufficient evidence that use of antifungals with antibiofilm activity has additional benefits, our experience indicates it may be recommendable.

Original languageEnglish
Pages (from-to)151-157
Number of pages7
JournalJournal of Infection
Issue number2
Publication statusPublished - 1 Aug 2018


  • 2-stage treatment
  • Antibiofilm agents
  • Antifungal-loaded bone cement
  • Candida
  • Echinocandins
  • Fungal periprosthetic infection


Dive into the research topics of 'Candida periprosthetic joint infection: A rare and difficult-to-treat infection: A rare and difficult-to-treat infection'. Together they form a unique fingerprint.

Cite this